April 30 Clinical Quick Takes: Xencor, Axovant, Cell Medica

Partial hold lifted on Xencor's blood cancer bispecific
FDA lifted a partial clinical hold on a Phase I trial of XmAb14045 from Xencor

Read the full 228 word article

User Sign In